Glaxosmithkline Pharmaceuticals Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/m8owivvi6072v422tnuabqj3.pdf

Key Takeaways


General Medicines: The Quarter That Wasn't

Bhushan Akshikar: "All the remediation is behind us. So, the good news is as we speak with October behind us, we clearly have moved full stream on the remediation."

Vaccines & Specialty: The Growth Engine


Margins: A 250 bps Jump, With Nuance

Juby Chandy: "80%-85% of the products are high margin products. On that context, we are not defocusing those high margin products that are growing much faster than the low margin imported products, that's where we are sustaining the margins."

Portfolio Transformation & Pipeline

Bhushan Akshikar: "Within the wider GSK family as a corporation, there are not too many countries which can boast of having not only endured but also created so much impact at scale as we have done in India."

Guidance & Commitments

CommitmentSpecificsTimeline
Supply normalizationCMO fire fully remediated; all supply constraints behind the companyFrom Q3 FY26 onward
GST impact reversalTransitionary GST reform impact (₹30–32 cr) to come back in a strong wayQ3 FY26
Double-digit growth ambitionAspiration and objective remains intact and undiluted in resourcing and wherewithalNo date (ongoing aspiration)
Gross margin improvementFull-year gross margin improvement to be sustained; raw material prices stableFull-year FY26
Oncology coverage updateMore details on reach and coverage to be shared once a full quarter is completeQ3 FY26
EBITDA margin sustainabilityManagement believes current margin levels are sustainable, with focus on expanding gross margins and cost consciousnessOngoing
Next pipeline assetsA couple of assets potentially coming in oncology and specialty areasNext financial year

Key Metrics

MetricQ2 FY26
Revenue₹974 cr, decline of 2.6% YoY
EBITDA margin34.4%, 250 bps improvement YoY
Profit after tax150 bps improvement YoY
EPS₹15.06, 3% improvement YoY
Market share27.6%, improving over many quarters
General Medicines adjusted growth5% to 6% (excluding fire and GST impact); declined and remained flattish on a reported basis
Vaccines growthDouble-digit (paediatric and adult shingles combined)
Speciality growthIn excess of 20% (Nucala and Trelegy combined)
CMO fire top-line impact~₹40 cr in Q2; combined Q1+Q2 impact in excess of ₹70–75 cr
GST transitionary impact₹30–32 cr in Q2
Employee cost one-off reversal₹16 cr benefit in the quarter; employee costs flat excluding this
Acute segment market growthBelow 5% (Indian pharmaceutical market)
Oncology launch contribution~5 weeks of patient recruitment in Q2 following 15 August launch
General Medicines share of business~80% (or plus) of total business